Search Results

1 - 5 of 5 items :

  • "nanoparticles" x
  • Endocrinology, Diabetology x
Clear All
Adverse eff ects of polymeric nanoparticle poly(ethylene glycol)- block-polylactide methyl ether (PEG-b-PLA) on steroid hormone secretion by porcine granulosa cells

References Campagnolo L, Massimiani M, Magrini A, Camaioni A, Pietroiusti A. Physico-chemical properties mediating reproductive and developmental toxicity of engineered nanomaterials. Curr Med Chem 19, 4488-4494, 2012. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 3, 133-149, 2008. Du JZ, Tang LY, Song WJ, Shi Y, Wang J. Evaluation of polymeric micelles from brush polymer with poly(ε- caprolactone)-b-poly(ethyleneglycol) side chains as drug carrier

Open access
Expression of genes encoding IGFBPs, SNARK, CD36, and PECAM1 in the liver of mice treated with chromium disilicide and titanium nitride nanoparticles

References Alarifi S, Ali D, Alkahtani S. Mechanistic investigation of toxicity of chromium oxide nanoparticles in murine fi brosarcoma cells. Int J Nanomedicine 11, 1253-1259, 2016. Avci NG, Fan Y, Dragomir A, Akay YM, Akay M. Investigating the infl uence of HUVECs in the formation of glioblastoma spheroids in high-throughput three-dimensional microwells. IEEE Trans Nanobioscience 14, 790-796, 2015. Azar WJ, Azar SH, Higgins S, Hu JF, Hoffman AR, Newgreen DF, Werther GA, Russo VC. IGFBP-2 enhances VEGF gene

Open access
Nanotechnology for treatment of glioblastoma multiforme

, 4 ] With such a short median survival, it is essential that we uncover novel techniques to treat patients with GBM. Current research shows that the genetic profile of GBM is leading to resistance to TMZ and radiation, but a major battle in the treatment of GBM is drug delivery across the blood–brain barrier (BBB). There is hope for patients with GBM because nanotechnology has been able to demonstrate the ability to cross the BBB. A number of nanomaterials, including liposomes, nanoemulsion, polymeric micelles, and iron oxide nanoparticles (IONP) have been

Open access
Anticoagulation treatments related different types of vascular access on maintenance hemodialysis patient: A multicenter epidemiological investigation

in patients with chronic renal insufficiency. Chin J Pract Intern Med 2011;31:333-5. 13. Kerr P, Perkovic V, Petrie J, Agar J, Disney A, Caring for Australians with Renal Impairment (CARI). The CARI guidelines. Dialysis adequacy (HD) guidelines. Nephrology (Carlton) 2005;10 (Suppl 4):S61-80. 14. Suranyi M, Chow JS. Review: Anticoagulation for haemodialysis. Nephrology (Carlton) 2010;15:386-92. 15. Stevens KN, Croes S, Boersma RS, Stobberingh EE, van der Marel C, van der Veen FH, et al. Hydrophilic surface coatings with embedded biocidal silver nanoparticles and

Open access
Micro RNAs: an arguable appraisal in medicine

.1158/1535-7163.MCT-14-0209 Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070, 2010. Deng Y, Wang CC, Choy KW, Du Q, Chen J, Wang Q, Li L, Chung TK, Tang T. Th erapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Genes 538, 217−227, 2014. Devalliere

Open access